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An attempt was made to clarify the effect of anthralin on epidermal cell kinetics. 
Commercial anthralin powder was separated by column chromatography into three 
components: pure anthralin, 1,8-dihydroxyanthraquinone, and anthralin dimer. The effect of 
these on the diurnal mitotic variation and the cell cycle of the hairless mouse epidermis was 
studied. Neither anthraquinone nor the anthralin dimer had any influence on these 
parameters. Both the chromatographically pure and commercial anthralins had similar 
effects. Mitotic activity was considerably reduced, although not to zero, with concomitant 
elimination of the diurnal peak. The Ga and S phases of the cell cycle were approximately 
doubled in length. Application of the pure and commercial anthralin also resulted in some 
irritation not seen with either the anthraquinone or dimer. 
The first use of anthralin (1,8,9-trihydroxyan-
thracene) for topical therapy of psoriasis was 
derived from a report on chrysarobin, a related 
compound, in 1878 [1]. In treating psoriatic lesions 
with commercial anthralin, two side effects have 
been documented: staining of skin and clothing, 
and irritation of surrounding normal skin. This 
report is, in part, directed toward determining 
whether the therapeutic effect and side effects of 
commercial anthralin are caused by the pure 
anthralin or a contaminant. Ponec-Waelsch and 
Hulsebosch (2] have suggested that anthralin oxi-
dation occurs in the presence of an adsorbing 
surface in a moist environment; resulting in a pink 
to violet discoloration and an ineffective prepara-
tion. Whitefield [3] indicated that oxidation im-
mediately before or after application to the skin 
could result, respectively,in irritation and staining 
during anthroquinone formation. 
Psoriasis is a skin disease characterized in part 
by epidermal hyperplasia and which should there-
fore be controllable with antimetabolic drugs. It 
has been assumed that anthralin is acting in this 
manner, i.e., by blocking cell division, but little 
work has been done to confirm this. Swan beck and 
his collaborators (4,5] have indicated that an-
thralin inhibits DNA synthesis in guinea-pig epi-
dermis and this may be due to binding with the 
DNA molecule. However, this does not correlate 
with our inability to demonstrate antimitotic ac-
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tion on normal human skin [6]. 
The effect on psoriatic epidermis is also in 
dispute. Baxter and Stoughton [7] demonstrated a 
significant decrease in the mitotic activity. Fry and 
McMinn [8] showed reformation of the granular 
layer after 7 days, but no significant fall in mitosis 
.until after 3 weeks of treatment; while Born [9] was 
unable to show any effect on DNA synthesis for up 
to 5 weeks after initiating treatment. Steigleder et 
al [10] and Pullman et al [11] have measured the 
epidermal cell kinetics of psoriatic lesions in vitro 
and indicate that DNA synthesis is slower than 
normal, i.e., S is longer for psoriatic cells than 
normal cells. Steigleder et a! [10] also show that 
anthralin returns the kinetics to normal in their 
system, i.e., anthralin would be speeding up DNA 
synthesis in psoriatic cells. However, irritation is a 
possible source of error since this has been shown to 
cause an increase in mitotic activity of the epider-
mis [12; Fisher, unpublished data]. In the follow-
ing work, the known anthroquinone and dimer [13] 
were separated from pure anthralin in the commer-
cial product to determine which of these may be 
responsible for any effect on the epidermal cell 
cycle. 
MATERIALS AND METHODS 
Purified anthralin, anthraquinone, and anthralin 
dimer were separated from commerdal crude anthralin 
by silica gel column chromatography. Silica gel G was 
suspended in heptane and poured into a l-inch column so 
that the settled height was 4 inches. The column was 
then equilibrated with a mixture of benzene, chloroform, 
and heptane (1:1:1). One hundred milligrams of crude 
anthralin dissolved in 2 ml of chloroform was placed on 
the column and the fractions were separated using the 
chloroform-benzene-heptane mixture. The pale, yellow-
colored anthralin moved most rapidly, followed by the 
orange anthraquinone and deeper yellow dimer. A brown-
violet colored contaminant remained at the top of the 
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column. When the· pun~ antbralin l«YU n!llChed the end 
of the column, the .column was dismantled, the various 
gel bands remond, and the compowids were eluted from 
the gel with btlptane. The various eluates were dried 
muler nitrogen and lelluapended in ethyl acetete. The 
purif'Jed compounds were identified by their absorption 
spectra and by thin-layer chromatography according to 
the method of Segal et al [13 ]. 
Adult male hairless mice, age 3 to 4 months, were used 
in this study. All animals -re injected with 30 pc of 
tritiated thymidine (27.0 mCi/mM} at 6:00 .u~ ± 15 
min. One group of 39 animals had no further treatment, 
while 24 pg of commercial anthralin in 0.1 ml of ethyl 
acetate (EtAc) was pipetted onto the backs of a second 
group immediately after thymidine injection. In a subse-
quent experiment (later date, same time of day), groups 
of Z1 animals were treated with the same quantities of 
either purified anthralin, anthralin d:imer, or anthraqui-
none. At this time, two groups of 18 animals were also 
used to determine the effect of 0.1 ml EtAc alone and to 
confirm the effect of commercial (nonpuritied) anthralin. 
Immediately after treatment 3 animals from each 
group were killed by neck pulling. This was repeated at 
varying intervals (see Figures for specific times). Speci-
mens of skin were removed from the treated (lumbar) 
regions of the back and f'a:ed in Bonin's solution. Stan-
dard techniques were used for wax embedding the 
specimens. Sections were then cut at 4 p, dipped in 
Kodak NTB-2 emulsion, and maintained in a light-tight 
box containing "Drierite" at 4GC for 21 days. Subse-
quently, the slides were developed and then stained with 
hematoxylin and eosin. From these specimens the mitotic 
index (mitoses per thousand viable epidermal cells [14]) 
and the percent labeled mitoses were counted using a 
hand tally counter. A minimum of 50 labeled mitoses 
were counted from each animal. The mitotic index was 
plotted against the time of day, and to determine the cell 
cycles, percent labeled mitoses were plotted against time 
after 'H-TdR injection. 
RESULTS 
A review of the histology of the animals showed 
that the doubling of epidermal thickness, probably 
indicative of irritation, occurred with both the 
commercial and the purified anthralin beyond 24 
hr after application. This was not observed with 
the quinone and the dirner. Gross observation of 
the skin showed slight orange-yellow staining with 
the pure anthralin and marked orange staining 
with the quinone. The chromatographically puri-
fied compounds were stable in vitro extending 
beyond the period of these experiments, although 
no statement can be made with regard to the 
situation on the animals' skins. However, over a 
period of several weeks in the test tube, the 
purified anthralin, anthroquinone, and anthralin 
dimer converted to a brown-violet compound al-
though-this color staining was not observed on the 
mice during the experimental period. 
Diurnal Mitotic Activity 
Those animals which had been treated only 
with ethyl acetate showed no difference from the 
typical diurnal mitotic variation normally seen in 
untreated animals (Fig. 1o), i.e., a peak mitotic 
activity was found at 24-hr intervals occurring at 
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FIG. 1. The diurnal mitotic cycle of hairless mouse 
epidermis. a. A- -A, Untreated animals; e, treatment 
with 0.1 ml ethyl acetate (EtAc); 0-----0, treatment 
with 0.1 ml purified anthralin/EtAc; A--A, treatment 
with 0.1 ml commercial anthralin/EtAc. All treatment 
applications at time 0. b . .6.- -A, Untreated animals; 
0--0, treatment with 0.1 ml anthroquinone/EtAc; 
•-----•. treatment with 0.1 anthralin dimer/EtAc. 
approximately 8:00 AM. Animals whose skins had 
been treated with either the commercial anthralin 
or the pure anthralin showed a profound inhibition 
at 4 hr followed by some variability about the 
control values for the next 14 hr (Fig. la). However, 
the expected peak, seen in the control animals at 
around 8:00 AM, did not occur. Mitotic activity 
fell to a minimum at approximately 10 hr after 
drug application and no significant recovery from 
this value was seen for the 34-hr duration of the 
experiment. This difference was significant at p < 
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.01 level. Those animals which had been treated 
with the quinone and also the dimer showed no 
significant difference as compared with the control 
groups (Fig. 1b) except at 4 hr where some mitotic 
inhibition was seen. 
Cell Cycle Analysis 
Those animals whose skins had been treated 
with ethyl acetate alone (Fig. 2a) showed no 
difference in cell cycle analysis from that of the 
untreated controls. The duration of the S phase as 
calculated from the 37.5% level of the peak was 
approximately 6 hr. Animals treated with either 
the commercial or the purified anthralin, however, 
showed an S phase increased to approximately 12 
hr (Fig. 2a). The peak of labeled mitoses was also 
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FIG. 2. The cell cycle analysis curve of hairless mouse 
epidermis. a. 11- -11, Untreated animals; e, treatment 
with 0.1 ml EtAc; Q ..... Q, treatment with 0.1 ml 
purified anthralin/EtAc; &--&, treatment with 0.1 ml 
commercial anthralin/EtAc. b. 11- -11, Untreated ani-
mals; 0--0, treatment with 0.1 ml anthroqui-
none/EtAc; e ..... e, treatment with. 0.1 ml anthralin 
dimer/EtAc. All treatment applications at time 0. 
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gested an increase in the G2 duration from 3.5 hr to 
6 to 9 hr. However, the anthraquinone and an-
thralin dimer caused no change in cell cycle 
kinetics as compared to the untreated animals 
(Fig. 2b). Since the data could be interpreted to 
indicate two effects-some cells being completely 
blocked and others only slowed in their passage 
through the cell cycle-it is possible that, for some 
reason, the latter received Jess anthralin than the 
former. An attempt was made to reduce mitotic 
activity to zero by applying anthralin 3 times at 
3-hr intervals starting, as in earlier experiments, at 
6:00 AM. Animals were killed at 3:00 PM, i.e., 12 
hr after the first application. The results in the 
Table show that this treatment did not produce 
any greater inhibition than a single application. In 
fact, the mitotic activity was higher after 3 appli-
cations, which could possibly be explained on the 
grounds of irritation. 
DISCUSSION 
Since an approximate doubling of epidermal 
thickness was seen after anthralin treatment, this 
might have artificially produced a decrease in 
mitotic activity. It is, however, unlikely since the 
hyperplasia was not apparent until about 24 hr 
after treatment, at which time the fall in mitosis 
was well established. With the protocol used in this 
experiment, any alteration of epidermal cell ki-
netics appears due to the effect of the anthralin as 
such, and not to either of the two "impurities" 
found in the commercial product. Apparently epi-
dermal cell production is slowed in two ways: 
Firstly, both the S and G, phases of the cell cycle 
are lengthened and this could explain the very 
early fall in mitotic index seen in Figure 1a. 
Secondly, the cells producing the diurnal mitotic 
peak are prevented from dividing by a single 
anthralin application. The data in the Table 
indicate that anthralin is acting as a complete cell 
cycle block on one portion of the proliferative pool 
while only slowing the remainder during G, and S. 
TABLE. The effect of multiple anthralin applications on 
the mitotic activity of hairless mouse epidermis 
Untreated Single" Multiple~ 
control application applications 
1.06 1.08 1.52 
3.57 0.44 1.70 
1.85 1.17 L32 
2.32 0.83 1.20 
1.00 0.92 1.02 
1.66 0.81 1.49 
Mean ± 1.91 ± 0.39 0.88 ± 0.10 1.38 ± 0.10 
S.E. 
"24 l'g anthralin in 0.1 ml EtAc applied at 6:00 AM. 
• Three applications of anthralin at 6:00 AM, 9:00 AM, 
and 12:00 noon 0.1 ml EtAc applied at 6:00AM to controls. 
Control vs 1 application p < 0.05. 
Control vs 3 applications p ~ 0.05. 
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These results could also explain why little or no 
effect was seen in our earlier treatment of normal 
human skin with anthralin [6). Although anthralin 
does indeed depress mitotic activity, the minimum 
seen after treatment does not fall significantly 
below the normal daily minimum. The time at 
which specimens were taken in our treatment of 
human skin was at approximately 3:00 PM, which 
is the normal daily minimum for human skin. It is 
thus possible that our finding in this instance was 
due to the use of inappropriate timing. This work 
will have to be pursued on human material for 
confirmation. Preliminary (unpublished) data in-
dicate that anthralin may be having a similar 
effect on psoriatic lesions, i.e., there is mitotic 
inhibition at 8:00 AM but not at 4:00 PM after 
prior application of the drug in ethyl acetate. 
Any effect on epidermal cell kinetics, and there-
fore possibly any therapeutic effect in psoriasis, is 
due to anthralin and not to either the quinone or 
dimer which are also found in the commercial 
product. Also the oxidation products of anthralin, 
which showed no biologic activity in the system 
described here, are much more intensely colored 
than the purified drug. This provides a reasonable 
explanation for the finding of Comaish et al [15) 
that discolored anthralin pastes (possibly contain-
ing large amounts of the quinone) are ineffective in 
treating psoriasis. 
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